| Literature DB >> 17540040 |
Li-Jen Su1, Ching-Wei Chang, Yu-Chung Wu, Kuang-Chi Chen, Chien-Ju Lin, Shu-Ching Liang, Chi-Hung Lin, Jacqueline Whang-Peng, Shih-Lan Hsu, Chen-Hsin Chen, Chi-Ying F Huang.
Abstract
BACKGROUND: The development of microarrays permits us to monitor transcriptomes on a genome-wide scale. To validate microarray measurements, quantitative-real time-reverse transcription PCR (Q-RT-PCR) is one of the most robust and commonly used approaches. The new challenge in gene quantification analysis is how to explicitly incorporate statistical estimation in such studies. In the realm of statistical analysis, the various available methods of the probe level normalization for microarray analysis may result in distinctly different target selections and variation in the scores for the correlation between microarray and Q-RT-PCR. Moreover, it remains a major challenge to identify a proper internal control for Q-RT-PCR when confirming microarray measurements.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17540040 PMCID: PMC1894975 DOI: 10.1186/1471-2164-8-140
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Flow chart for prioritization of potential internal controls.
Figure 2Bootstrap box plots of the gene expression intensity of various internal controls. (A) The box plot results show the best 14 internal control candidates, all of which exhibited consistent expression intensity in the NHRI lung adenocarcinoma microarray dataset for each re-sampling process. Moreover, also included are 10 well-known Q-RT-PCR internal controls contained in 23 probe sets on the HG-U133A chip. These are shown as #1–23 in x-axis. The detailed probe set characteristics were shown in Table 1. Except ABCF1, BHLHB2 and LAPTM4A, the gene expression intensities of top 12 internal control candidates, GAPDH, and ACTB from the Boston (B) and the Ann Arbor lung cancer datasets (C) were also compared. DDX5: (DEAD (Asp-Glu-Ala-Asp) box polypeptide 5), PKM2: (pyruvate kinase, muscle), BHLHB2: (basic helix-loop-helix domain containing, class B, 2), GLO1: (glyoxalase I), LAPTM4A: (lysosomal-associated protein transmembrane 4 alpha), SET: (SET translocation (myeloid leukemia-associated)), CLTC: (clathrin, heavy chain (Hc)), MSN: (MSN/ALK fusion; moesin/anaplastic lymphoma kinase fusion protein), ABCF1: (ATP-binding cassette, sub-family F (GCN20), member 1), EPHB3: (EPH receptor B3), CCL5: (chemokine (C-C motif) ligand 5), PTPN21: (protein tyrosine phosphatase, non-receptor type 21), DDR1: (discoidin domain receptor family, member 1), 1–4: ACTB (actin, beta), 5–6: B2M (beta-2-microglobulin), 7–12: GAPDH (glyceraldehyde-3-phosphate dehydrogenase), 13: HMBS (hydroxymethylbilane synthase), 14: HPRT1 (hypoxanthine phosphoribosyltransferase 1), 15–19: RPL13A (ribosomal protein L13a), 20: RPL32 (ribosomal protein L32), 21: SDHA (succinate dehydrogenase complex, subunit A, flavoprotein (Fp)), 22: UBC (ubiquitin C), 23: YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide).
Summary of probe set characteristics of 10 well-known internal controls for Q-RT-PCR in Affymetrix HG-U133A chip
| ACTB | AFFX-HSAC07/X00351_M_at | no | 1 |
| AFFX-HSAC07/X00351_5_at | no | 2 | |
| AFFX-HSAC07/X00351_3_at | no | 3 | |
| 200801 _x at | yes | 4 | |
| GAPDH | AFFX-HUMCAPDH/M33197_M_at | no | 5 |
| AFFX-HUMGAPDH/M33197_5_at | no | 6 | |
| AFFX-HUMGAPDH/M33197_3_at | no | 7 | |
| 217398_x_at | yes | 8 | |
| 213453_x at | yes | 9 | |
| 212581_x_at | yes | 10 | |
| B2M | 216231_s_at | yes | 11 |
| 201891_s_at | yes | 12 | |
| HMBS | 203040_s_at | no | 13 |
| HPRT1 | 202854_at | no | 14 |
| RPL13A | 212790_x_at | yes | 15 |
| 211942_x_at | yes | 16 | |
| 210646_x_at | yes | 17 | |
| 200716_x_at | yes | 18 | |
| 200715_x at | yes | 19 | |
| RPL32 | 200674_s_at | no | 20 |
| SDHA | 201093_x_at | yes | 21 |
| UBC | 211296_x_at | yes | 22 |
| YWHAZ | 214848_at | no | 23 |
Figure 3Bootstrap replicates of the descriptive statistics related to the variation in gene expression. In total, 27 pairs of adjacent normal and tumor samples with 12 un-paired samples were used in this analysis. A total of 39 blocks of microarray samples were used for the block bootstrap. The re-sampling process was repeated 1,000 times to obtain 1,000 bootstrap replicates of the minimum (green color), first quartile (red color), median (black color), third quartile (blue color) and maximum (cyan color) expression levels for each gene. Each result was ranked by the order of medians. The bootstrap replicates of all five statistics for DDX5 expression remain roughly constants, but those for GAPDH expression vary greatly.
Figure 4Gene expression patterns of . The gene expression patterns of two internal controls, DDX5 (A) and GAPDH (B: 212581_x_at and C: M33197_3_at) from Affymetrix chips by MAS5 (marked by diamonds), RMA (marked by squares) and GC-RMA (marked by triangles) probe level quantile normalizations. Normalization was performed per chip and per gene using GeneSpring® 7.3 software. The expression levels of these two internal controls were related to the median of the intensities on the 66 chips. The DDX5 expression patterns in each chip did not significantly alter compared to greater variation in GAPDH.
Summary of the correlations between microarray and Q-RT-PCR analyzed by Pearson's and Kendall's τ correlations.
| ASK | 0.13 | -0.16 | 0.14 | -0.19 |
| BUB1B | 0.53 | 0.47 | 0.39 | 0.33 |
| CDCA8 | 0.68* | 0.49 | 0.52* | 0.36 |
| CENTD2 | 0.65** | 0.16 | 0.50** | 0.05 |
| CXCL5 | 0.62** | 0.60** | 0.39** | 0.34* |
| CYP27A1 | 0.30 | 0.53** | 0.19 | 0.41** |
| FLJ10540 | 0.70** | 0.35 | 0.50** | 0.16 |
| FLJ20530 | 0.54** | -0.14 | 0.40** | -0.08 |
| FLJ20605 | 0.03 | 0.25 | 0.01 | 0.18 |
| FY | 0.47* | 0.52* | 0.30* | 0.34* |
| FZD4 | 0.45* | 0.42 | 0.28 | 0.25 |
| GARP | 0.55* | 0.53* | 0.24 | 0.26 |
| MMP9 | 0.70** | 0.64** | 0.54** | 0.49** |
| MSR1 | 0.79** | 0.79** | 0.50** | 0.57** |
| PA26 | 0.56** | 0.68** | 0.35* | 0.49** |
| S100A2 | 0.67** | 0.57** | 0.42** | 0.38** |
| SERPINA3 | 0.70** | 0.49 | 0.49* | 0.41* |
| SOX4 | 0.11 | 0.14 | -0.06 | -0.03 |
| SRD5A1 | 0.69** | 0.61** | 0.50** | 0.37* |
| T1A-2 | 0.31 | 0.19 | 0.22 | 0.13 |
| TEK | 0.41 | 0.47* | 0.24 | 0.32* |
| TOPK | 0.58** | 0.28 | 0.39* | 0.16 |
| TROAP | 0.60** | 0.46* | 0.40** | 0.30* |
*: P < 0.05, **: P < 0.01.
Figure 5Box plots of . The gene expression patterns of DDX5 were obtained from other microarray databases. These datasets were from 84 cancer cell lines (NCI60), which were classified into 8 different cancer cell types and other cell lines (A). GAPDH #5: M33197_3_at; GAPDH #10: 212581_x_at. The box plot results indicated that DDX5 exhibited only small variation across the various NCI60 cell types. For the lung cancer cell lines, DDX5, CLTC and MSN all gave lower variances than ACTB and GAPDH (B). Both ACTB (#1–4) and GAPDH (#5–10) are contained in 10 probe sets on the HG-U133A chip and are shown as #1–10 on x-axis and in Table 1. The variation of DDX5 was also smaller for the HeLa cell cycle dataset, lung cancer dataset and HCC dataset from the Stanford Microarray Database (C). BR: breast cancer, CO: colon cancer, GL: glioblastoma, KI: Kidney, LE: leukemia, LU: lung cancer, ME: melanoma and OV: ovarian cancer.
Summary table of Assays-on-Demand ID of 23 genes and 2 internal controls for Q-RT-PCR.
| ASK | activator of S phase kinase | Hs00272696_m1 |
| BDB1B | BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) | Hs00176169_m1 |
| CDCA8 | cell division cycle associated 8 | Hs00216479_m1 |
| CKNTD2 | centaurin, delta 2 | Hs00362929_m1 |
| CXCL5 | chemokine (C-X-C motif) ligand 5 | Hs00171085_m1 |
| CYP27A1 | cytochrome P450, family 27, subfamily A, polypeptide 1 | Hs00168003_m1 |
| FLJ10540 | chromosome 10 open reading frame 3 | Hs00216688_m1 |
| FLJ20530 | hypothetical protein FLJ20530 | Hs00215334_m1 |
| FLJ20605 | hypothetical protein FLJ20605 | Hs00215486_m1 |
| FY | Duffy blood group | Hs00266671_s1 |
| FZD4 | frizzled homolog 4(Drosophila) | Hs00201853_m1 |
| GARP | glycoprotein A repetitions predominant | Hs00194136_m1 |
| MMP9 | matrix metalloproteinase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) | Hs00234579_m1 |
| MSR1 | macrophage scavenger receptor 1 | Hs00234007_m1 |
| PA26 | sestrin 1 | Hs00205427_m1 |
| S100A2 | S100 calcium binding protein A2 | Hs00195582_m1 |
| SERPINA3 | serine (or cysteine) proteinase inhibitpr, clade A (alpha-1 antiproteinase, antitrypsin), member 3 | Hs00153674_m1 |
| SOX4 | SRY(sex determining region Y)-box 4 | Hs00268388_s1 |
| SRD5A1 | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase | Hs00602694_mH |
| alpha 1) | ||
| T1A-2 | lung type-I cell membrane-associated glycoprotein | Hs00366764_m1 |
| TEK | TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal) | Hs00176096_m1 |
| TOPK | T-LAK cell-originated protein kinase | Hs00902988_m1 |
| TROAP | trophinin associated protein (tastin) | Hs00193896_m1 |
| DDX5 | DEAD (Asp-(Glu-Ala-Asp) box polypeptide 5 | Hs00189323_m1 |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase | Hs99999905_m1 |